Genelux Corporation Presents Abstracts at 2013 ASCO Annual Meeting for Clinical Trials of GL-ONC1, Its Oncolytic Virus Lead Product Candidate
30 mai 2013 07h30 HE
|
Genelux Corporation
SAN DIEGO, CA--(Marketwired - May 30, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapies and companion diagnostics, today...
Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients
28 juin 2012 11h00 HE
|
Genelux Corporation
SAN DIEGO, CA--(Marketwire - Jun 28, 2012) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion...